title: Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases.
authors.forename: R
authors.initials: R
authors.lastname: Rios-Fernández
authors.forename: M T
authors.initials: MT
authors.lastname: Gutierrez-Salmerón
authors.forename: J-L
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: M
authors.initials: M
authors.lastname: Fernández-Pugnaire
authors.forename: N
authors.initials: N
authors.lastname: Ortego-Centeno
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D010392:Pemphigus / Q000150:complications* / Q000188:drug therapy; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab